Coronavirus Covaxin vaccine update: India’s first, largest phase 3 human trials of Covid-19 vaccine begin

By: |
New Delhi | Updated: Nov 18, 2020 10:34 AM

Coronavirus vaccine in India: Phase 3 human trials of Covaxin is the largest clinical trial conducted for a potential Coronavirus vaccine in India. This is also India's first phase 3 efficacy study for a Covid-19 vaccine.

Coronavirus vaccine, Coronavirus vaccine India, Coronavirus vaccine update, Coronavirus vaccine update Delhi, Coronavirus vaccine update India, Coronavirus vaccine news, Coronavirus vaccine India, Coronavirus vaccine tracker, Coronavirus vaccine latest news, Coronavirus vaccine progress, Coronavirus vaccine latest update, covid 19 India, covid 19 vaccine, covid 19 vaccine updateCoronavirus vaccine in India: India's indigenous Coronavirus vaccine Covaxin is being developed by Bharat Biotech along with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

Coronavirus vaccine in India: The phase 3 human trials of India’s indigenous experimental Coronavirus vaccine candidate Covaxin is beginning, manufacturer Bharat Biotech has said. The large-scale late-stage clinical trials of COVAXIN will involve 26,000 volunteers across India. The phase 3 clinical trials of Covaxin Covid-19 vaccine candidate are being done in collaboration with the Indian Council of Medical Research (ICMR), according to PTI report

Covaxin Phase 3 human trials in India

Phase 3 human trials of Covaxin is the largest clinical trial conducted for a potential Coronavirus vaccine in India. This is also India’s first phase 3 efficacy study for a Covid-19 vaccine, as per Indian Express report.

During phase 3 human trials, volunteers will be inoculated with two intramuscular injections which will be administered around 28 days apart.

Volunteers will be randomly selected to receive COVAXIN or placebo. The human trial of Covaxin is double-blinded. The investigators, volunteers and the manufacturer will not know who is assigned to which group.

In October, Bharat Biotech said it had successfully completed an interim analysis of Phase I and II human trials of Covaxin, as per PTI report.

During phase 1 and Phase 2 human trials of Covaxin, around 1000 volunteers were monitored for safety and immunogenicity data. Volunteers aged over 18 must participate in human trials of Covaxin.

India’s indigenous Coronavirus vaccine Covaxin is being developed by Bharat Biotech along with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). Bharat Biotech Chairman and Managing Director Krishna Ella said that the firm tied up with ICMR for COVID-19 vaccine phase 3 trials.

What is the importance of Covaxin Phase 3 human trials in India

India is hoping the “locally-tested” Coronavirus vaccines will help it to control Coronavirus, as the experimental Covid-19 vaccines developed by Pfizer-BioNTech and Moderna may not be available to it in big quantities soon, as per a Reuters report. One of these potential Coronavirus vaccines is Covaxin.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19: Maharashtra extends lockdown restrictions till December 31
2Covid-19 vaccine: Visit by foreign envoys to Pune pharmaceutical firms canceled
3COVID-19 caseload: 10 states have almost 77% of active cases in country, Centre tells SC